The Volatile Fraction: Heat, Occlusion and What a Threshold Model Cannot See
A margin of safety is only as honest as the assumptions beneath it.
Volatile compounds carry that name because they leave the material holding them and enter the air, and they leave faster as temperature rises; vapor pressure roughly doubles for every ten-degree increase. Every published risk assessment of sanitary pads rests on measurements of how much comes off a pad in a laboratory, at bench temperature, in open air. None of them examined a pad that spent four months in a storeroom off Aba Road and then six hours inside underwear at thirty-seven degrees, behind a polyethylene seal that lets nothing escape. Reassurance drawn from those studies is real reassurance, and what it describes is a pad on a bench.
Korean investigators produced the most thorough assessment available, and it repays reading in detail. Seventy-four volatile compounds were sought in pads retailed in Korea; fifty were recovered, at concentrations from 0.025 to 3,548.09 micrograms per pad. Systemic exposure doses were derived for each, ranging from 1.74 nanograms per kilogram of body weight per day for a trichloroethane isomer to 144.4 micrograms per kilogram per day for ethanol. Uncertainty factors from ten to one hundred thousand were applied according to the strength of the underlying toxicological data. Margins of exposure exceeded one for thirty-four compounds, calculated cancer risk for five fell below one in a million, and the authors reported that neither cancer nor non-cancer risk at Korean usage levels appeared appreciable.
Weight should be given to that conclusion. It was reached by investigators with no commercial interest in the outcome, using standard methodology, and reported plainly. Equal weight belongs on what a worst-case exposure scenario means in practice, which is that conservative values were selected for the variables modeled, and that every figure downstream depends on which variables entered the model at all.
Illinois testing came at the same compound class from another direction. Methylene chloride, toluene and xylene were measured across eleven brands of pad drawn from six national markets. Air inside sealed packaging carried volatile content up to 5.9 parts per billion. Methylene chloride, a paint stripper, appeared in two brands; toluene in nine; xylene in every brand tested. Between the highest and lowest brand ran a spread of five thousand nine hundred-fold.
Michigan investigators widened the frame beyond pads to seventy-nine feminine hygiene products, including washes, wipes, sprays and powders, analyzed by purge and trap sampling with thermal desorption and gas chromatography. Washes, sprays and powders carried the heaviest burdens, with median totals in the tens of thousands of nanograms per gram. Benzene turned up in eighty-three percent of products, to a maximum of 3,604 nanograms per gram, and 1,4-dioxane in half of them, to a maximum of 24,354. Products marketed as organic, natural or suitable for sensitive skin did not reliably carry less than the rest.
Of everything in this part, that last result is the one most likely to alter what a reader does this week. Premium pricing on a reassurance claim purchased nothing measurable in the dataset, and none of those three words carries a regulatory definition anyone could enforce against a manufacturer.
Recent work narrows the picture, and it belongs here rather than in a footnote, since a file reporting only the alarming half would deserve everything said about it afterward. Twenty-nine commercial pads screened for ten target compounds yielded toluene alone, from 0.09 to 2.79 micrograms per pad, in twenty-eight of twenty-nine products, with benzene, xylene, styrene and chloroform all below the limit of quantification. Modeled exposure came in under health-based thresholds. Citing this series as evidence that pads are saturated with solvents misrepresents what the evidence carries.
Three limitations run through all of it. None constitutes an attack on the investigators, who measured what they set out to measure and described their methods openly.
Temperature is the first and the least defensible. Every figure quoted above was generated in a laboratory. Product reaching Nigerian consumers passes through unconditioned warehousing, open-air markets and back rooms holding above thirty-five degrees for months at a stretch, then spends hours against a body at thirty-seven. Package headspace already carried measurable volatile content at bench temperature. What that headspace holds after a hot season in Kano has never been determined, and no study consulted for this part attempted it.
Selection is the second. A screen for ten compounds returns information about ten compounds and silence about everything else. Korean work sought seventy-four and recovered fifty, which shows plainly that the answer depends on how wide the net goes. Every threshold conclusion in this field is therefore a statement about the compounds somebody decided to look for, and about nothing beyond them.
Mixture is the third and, toxicologically, the most serious. Margins of exposure are calculated one compound at a time against reference doses derived one compound at a time. A woman does not receive toluene in isolation. She receives whatever the product emits, simultaneously, alongside fragrance chemistry, adhesive residue, and whatever her wash and laundry detergent contribute to the same square of skin. Reference dose methodology was never constructed to answer that question, and its practitioners have said so.
Wear time deserves separate treatment, being the variable a woman controls and the one no model examined. Every exposure estimate assumes a change interval, and the interval assumed is the one printed on the pack. Extended wear raises local temperature, drives the core toward saturation, and alters the surface chemistry meeting skin; a pad worn eight hours does not release on the same curve as one worn four. Nobody has plotted the second curve.
Occlusion compounds the problem in ways any clinician would predict. Vapor coming off the topsheet toward the body meets a polyethylene backsheet behind it and does not disperse into a room; it concentrates in a sealed space a few millimeters deep, warmed on one side by the body and bounded on the other by plastic, over epithelium whose stratum corneum is thin and already hydrated. Hydration itself raises permeability, which is the principle behind occlusive dressings in topical therapy and the reason potent steroids are used under occlusion with caution. Measuring emission into open air and measuring concentration inside that pocket are different measurements, and only the first has been performed.
Human measurement is where the argument stops being theoretical. One group examined women rather than products, comparing volatile compound biomarkers against reported feminine hygiene product use in a national survey of reproductive-aged women, and reported associations between use and measured biomarker levels. Cross-sectional design limits what that establishes; women using more of these products differ in other ways, and self-reported use is imprecise. What it does establish is that the question is answerable in people, with blood and urine, and that almost nobody has attempted it.
Objections at full strength. Volatile compounds are ubiquitous, present in residential air, cleaning products, cosmetics, vehicle interiors and building materials, and the Illinois group themselves observed that pad concentrations resembled ordinary indoor air. A pad worn for hours delivers a fraction of what a person inhales continuously. Independent groups on two continents modeled exposure below thresholds using conservative assumptions. Detection at parts per billion says as much about modern instrumentation as about hazard.
Answer each and the charge survives, because the charge concerns what was never measured. Ambient air comparisons address inhalation across the alveolar surface, not vapor held against vulvar epithelium under occlusion for six days a month. Conservative assumptions were conservative about dose and silent on temperature, mixture and duration. Below-threshold findings are the correct reading of the studies performed, and those studies were performed on pads from Seoul, Champaign and Ann Arbor, at laboratory temperature, one compound at a time.
Nobody has run this analysis on a pad bought in an African market, stored in African heat, worn in African humidity. Until somebody does, every reassurance offered to African women about the volatile fraction is an extrapolation, and those offering it are obliged to say so.
Forensic Exhibit Plate / Plate 4.1 — What The Model Assumed
Plate 4.1 — What the Model Assumed
Assumption audit setting each published exposure assessment against the conditions of African storage and wear.
Evidence Class: Documented — Model Parameters As Published
Forensic Exhibit Plate / Plate 4.2 — Fifty Of Seventy-four
Plate 4.2 — Fifty of Seventy-Four
Detection field for volatile organic compounds recovered from pads retailed in Korea, on a logarithmic concentration scale.
Evidence Class: Documented — Concentration Range And Count As Published
Forensic Exhibit Plate / Diagram 3 — The Occluded Pocket
Diagram 4.3 — The Occluded Pocket
Cross-section through a product in wear, showing the sealed space in which released vapor is held against the epithelium.
EVidence Class: Clinical Schematic — Documented Product Construction
Source & Clinical Standards
Note: The chemistry, clinical findings, regulatory benchmarks and analytical figures throughout this series are drawn directly from peer-reviewed medical and toxicological literature, independent laboratory analysis, published case reports and established regulatory frameworks. Anatomical plates are reference schematics prepared from the published descriptive literature and are not to scale. To protect the narrative rhythm of this layout, the individual bibliographies carried by each part have been unified.
A complete master registry—cataloging all underlying source literature, analytical studies, case reports, patent disclosures and institutional frameworks (including the World Health Organization, the United States Food and Drug Administration’s medical-device classification of menstrual products, European Union restrictions on leave-on biocides, the New York State menstrual-product disclosure law, and the standing NAFDAC position)—is compiled in full at the conclusion of the complete volume.
Every claim in this series is carried as documented, alleged or inferred, and no finding of criminal guilt is made against any individual. A standing right of reply is held open for every named party.
